RVX.TO - Resverlogix Corp.
Resverlogix Corp.
4820 Richard Road SW
Suite 300
Calgary, AB T3E 6L1
Canada
403-254-9252
https://www.resverlogix.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 19
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Donald J. McCaffrey | Co-Founder, Chairman, Pres, CEO & Sec. | 505.2k | N/A | N/A |
| Mr. Aaron Bradley Cann C.A., CPA, CA, CPA, CBV | Chief Financial Officer | 281.8k | N/A | N/A |
| Dr. Ewelina Kulikowski Ph.D. | Chief Scientific Officer | 250k | N/A | N/A |
| Dr. Jan O. Johansson M.D., Ph.D. | Sr. VP of Medical Affairs | 312.17k | N/A | N/A |
| Dr. Michael Sweeney M.D. | Sr. VP of Clinical Devel. | 511.56k | N/A | 1961 |
| Sarah Zapotichny | Director of Investor Relations & Corp. Communications | N/A | N/A | N/A |
Description
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada; and developing cardiovascular and pulmonary arterial hypertension indications. The company was founded in 2001 and is headquartered in Calgary, Canada.
Corporate Governance
Resverlogix Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
